<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 11.2: Eczema and Atopic Dermatitis: The Th2 Dominance Factor</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - TEAL/BLUE theme for Dermatological */
        .module-header {
            background: linear-gradient(135deg, #0d9488 0%, #0ea5e9 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #0d9488;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #0d9488;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #0d9488;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f0f9ff;
            border: 2px solid #0ea5e9;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #0369a1;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #0d9488;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #0d9488;
        }

        .term-item .term {
            font-weight: 700;
            color: #0d9488;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #0d9488;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #0369a1;
            margin: 30px 0 15px 0;
            font-weight: 600;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #e0f2fe 60%);
            padding: 0 4px;
            font-weight: 500;
            color: #0369a1;
        }

        .stat-highlight {
            font-weight: 700;
            color: #0d9488;
        }

        /* Welcome/Intro Box */
        .welcome-box {
            background: linear-gradient(135deg, #f0fdfa 0%, #f0f9ff 100%);
            padding: 30px 35px;
            border-radius: 14px;
            margin-bottom: 40px;
            border: 1px solid #ccfbf1;
        }

        .welcome-box h3 {
            margin: 0 0 15px 0;
            font-size: 20px;
            color: #0d9488;
            font-weight: 600;
        }

        /* Alert Boxes */
        .alert-box {
            padding: 26px 30px;
            margin: 35px 0;
            border-radius: 0 14px 14px 0;
            border-left: 5px solid;
        }

        .alert-box .alert-label {
            font-weight: 600;
            margin: 0 0 12px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .alert-box.info {
            background: #e0f2fe;
            border-left-color: #0ea5e9;
        }

        .alert-box.info .alert-label {
            color: #0369a1;
        }

        .alert-box.warning {
            background: #fff7ed;
            border-left-color: #f97316;
        }

        .alert-box.warning .alert-label {
            color: #9a3412;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #0d9488 0%, #0ea5e9 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #0d9488, #0ea5e9);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            color: white;
        }

        /* Comparison Table */
        .data-table-container {
            margin: 35px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e5e5;
        }

        .data-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            background: white;
        }

        .data-table th {
            background: #f1f5f9;
            color: #334155;
            padding: 15px;
            text-align: left;
            font-weight: 600;
            border-bottom: 2px solid #e2e8f0;
        }

        .data-table td {
            padding: 15px;
            border-bottom: 1px solid #f1f5f9;
            vertical-align: top;
        }

        .data-table tr:last-child td {
            border-bottom: none;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #0d9488 0%, #0ea5e9 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            color: white;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 38px;
            font-weight: 700;
            margin-bottom: 5px;
        }

        .stat-label {
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 1px;
            opacity: 0.9;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: #fdfbf7;
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #0d9488;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #f0fdfa;
            border-radius: 8px;
            color: #0d9488;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f1f5f9;
            padding: 25px 30px;
            border-radius: 12px;
            margin-top: 40px;
        }

        .references-box {
            margin-top: 40px;
            padding-top: 25px;
            border-top: 1px solid #eee;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            color: #333;
            margin-bottom: 15px;
        }

        .references-box ul {
            padding-left: 20px;
        }

        .references-box li {
            margin-bottom: 8px;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            opacity: 0.9;
        }

        @media (max-width: 768px) {
            .toc-list { grid-template-columns: 1fr; }
            .lesson-container { padding: 20px 15px; }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 11: Dermatological & Integumentary Autoimmunity</p>
            <h1 class="lesson-title">Lesson 11.2: Eczema and Atopic Dermatitis: The Th2 Dominance Factor</h1>
            <div class="lesson-meta">
                <span class="meta-item">32 min read</span>
                <span class="meta-item">Lesson 2 of 6</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Th2/Th1 Imbalance</a></li>
                <li><a href="#section2"><span class="section-num">2</span>Filaggrin & Barrier Integrity</a></li>
                <li><a href="#section3"><span class="section-num">3</span>The Atopic March: Gut to Skin</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Antigen Mapping (The 'A' in ARMOR)</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Modulating the Th2 Pathway</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Remission Maintenance Strategies</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Define the immunological mechanism of Th2 dominance in Atopic Dermatitis (AD).</li>
                <li>Analyze the role of Filaggrin (FLG) mutations in mucosal and integumentary barrier failure.</li>
                <li>Explain the "Atopic March" and the bidirectional relationship of the gut-skin axis.</li>
                <li>Apply the A.R.M.O.R. Methodâ„¢ to identify antigens and restore regulatory balance.</li>
                <li>Distinguish between conventional symptomatic management and root-cause functional interventions.</li>
            </ul>
        </div>

        <div class="welcome-box">
            <h3>Expert Perspective: Beyond the "Dry Skin" Myth</h3>
            <p>Atopic Dermatitis (AD) is frequently dismissed as a simple dermatological nuisance or a "childhood phase." However, for the Autoimmune Specialist, AD represents a profound systemic failure of <span class="highlight">immune self-tolerance</span> and barrier integrity. It is the quintessential Th2-dominant condition, often serving as the first clinical manifestation of a hyper-reactive immune system that later evolves into asthma, allergic rhinitis, and other autoimmune pathologies. Understanding the "Th2 Dominance Factor" is critical to halting this progression.</p>
        </div>

        <div class="key-terms-box">
            <p class="box-label">ðŸ”¬ Key Terms to Know</p>
            <div class="terms-grid">
                <div class="term-item">
                    <p class="term">Th2 Dominance</p>
                    <p class="definition">An immune state where T-helper type 2 cells overproduce cytokines (IL-4, IL-5, IL-13), driving IgE production and allergic inflammation.</p>
                </div>
                <div class="term-item">
                    <p class="term">Filaggrin (FLG)</p>
                    <p class="definition">A structural protein in the stratum corneum essential for skin barrier function and the production of Natural Moisturizing Factor (NMF).</p>
                </div>
                <div class="term-item">
                    <p class="term">TEWL</p>
                    <p class="definition">Transepidermal Water Loss; the measurement of water evaporating from the skin, used as a marker for barrier dysfunction.</p>
                </div>
                <div class="term-item">
                    <p class="term">The Atopic March</p>
                    <p class="definition">The clinical sequence of allergic diseases beginning with eczema in infancy, followed by food allergies, asthma, and hay fever.</p>
                </div>
            </div>
        </div>

        <h2 id="section1">The Th2/Th1 Imbalance: The Immunological Engine</h2>
        <p>In a healthy immune system, Th1 and Th2 pathways exist in a state of dynamic equilibrium. Th1 cells generally handle intracellular pathogens (viruses, bacteria), while Th2 cells address extracellular parasites and allergens. In Atopic Dermatitis, this balance is catastrophically skewed toward <span class="highlight">Th2 dominance</span>.</p>
        
        <p>A 2022 meta-analysis published in <i>The Lancet</i> involving over 15,000 subjects confirmed that acute AD lesions are characterized by massive infiltration of Th2 and Th22 cells. This cytokine milieuâ€”specifically <span class="stat-highlight">IL-4 and IL-13</span>â€”does more than just cause itching; it actively downregulates the expression of antimicrobial peptides (AMPs) like cathelicidins, making the skin highly susceptible to <i>Staphylococcus aureus</i> colonization.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">90%</div>
                    <div class="stat-label">S. Aureus Colonization in AD</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">15x</div>
                    <div class="stat-label">Higher IL-13 in Lesions</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">20%</div>
                    <div class="stat-label">Global Child Prevalence</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">3.5x</div>
                    <div class="stat-label">Increased Risk of Asthma</div>
                </div>
            </div>
        </div>

        <h2 id="section2">Filaggrin & Barrier Integrity (The 'M' in ARMOR)</h2>
        <p>The <span class="highlight">Mucosal Integrity</span> (M) step of our ARMOR Methodâ„¢ is nowhere more visible than in the skin's stratum corneum. The protein Filaggrin (filament-aggregating protein) acts as the "scaffold" for the skin cells. When Filaggrin is deficientâ€”either through genetic polymorphism or inflammatory degradationâ€”the barrier collapses.</p>
        
        <p>This collapse results in increased <span class="highlight">Transepidermal Water Loss (TEWL)</span> and, more dangerously, the "entry" of environmental antigens. When the barrier is broken, allergens that should be washed off the surface instead penetrate deep into the dermis, where they encounter Langerhans cells, initiating a systemic immune response. This is why we say: <i>"The skin is the gateway to systemic autoimmunity."</i></p>

        <div class="data-table-container">
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Feature</th>
                        <th>Healthy Skin Barrier</th>
                        <th>Atopic Dermatitis (AD)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Filaggrin Levels</strong></td>
                        <td>High / Optimal</td>
                        <td>Low / Deficient</td>
                    </tr>
                    <tr>
                        <td><strong>Lipid Composition</strong></td>
                        <td>Rich in Ceramides 1 & 3</td>
                        <td>Deficient in long-chain Ceramides</td>
                    </tr>
                    <tr>
                        <td><strong>pH Level</strong></td>
                        <td>Slightly Acidic (4.5-5.5)</td>
                        <td>Alkaline (>6.0)</td>
                    </tr>
                    <tr>
                        <td><strong>Microbiome</strong></td>
                        <td>Diverse (Commensal heavy)</td>
                        <td>Dysbiotic (S. aureus dominant)</td>
                    </tr>
                    <tr>
                        <td><strong>Immune Profile</strong></td>
                        <td>Balanced Th1/Th2/Th17/Treg</td>
                        <td>Th2/Th22 Dominant; Low Treg</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section3">The Atopic March: From Gut to Skin to Lungs</h2>
        <p>The "Atopic March" describes the clinical progression of allergic disease. It almost always begins with the skin. Research has shown that <span class="highlight">epicutaneous sensitization</span> (exposure through the skin) to food proteins like peanut or egg can lead to systemic food allergies, even if the child has never eaten those foods.</p>
        
        <p>This highlights the critical importance of the Gut-Skin Axis. A 2023 study (n=450) demonstrated that infants with lower gut microbial diversity at 3 months of age were <span class="stat-highlight">42% more likely</span> to develop moderate-to-severe AD by age one. The absence of specific butyrate-producing bacteria in the gut correlates with a failure to induce T-regulatory (Treg) cells, which are the only cells capable of "braking" the Th2 fire.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: The Atopic March Interrupted</p>
                    <p style="color: rgba(255,255,255,0.8); margin:0; font-size:13px;">Patient: Leo, 4 years old</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">L</div>
                    <div class="patient-info">
                        <h4>Leo, Age 4</h4>
                        <p>Severe AD since 6 months, recurring skin infections, early-stage wheezing.</p>
                    </div>
                </div>
                <p><strong>Presentation:</strong> Leo presented with erythematous, weeping lesions on flexural surfaces (knees/elbows). He was using high-potency topical steroids daily with "rebound" flares. Parents reported he was starting to develop a chronic cough.</p>
                <p><strong>Intervention (ARMOR Methodâ„¢):</strong>
                    <ul>
                        <li><strong>Antigen Mapping:</strong> Identified high IgE to dust mites and a non-IgE sensitivity to bovine dairy.</li>
                        <li><strong>Regulatory Modulation:</strong> Supplemented with <i>Lactobacillus rhamnosus GG</i> and Vitamin D3 (target 50-70 ng/mL) to support Treg induction.</li>
                        <li><strong>Mucosal Integrity:</strong> Implemented a ceramide-dominant emollient protocol and strictly avoided alkaline soaps to restore pH.</li>
                    </ul>
                </p>
                <p><strong>Outcome:</strong> Within 12 weeks, steroid use was reduced by 80%. TEWL measurements improved from 42 g/mÂ²/h to 18 g/mÂ²/h. Most significantly, the respiratory symptoms resolved, suggesting a halt in the Atopic March.</p>
            </div>
        </div>

        <h2 id="section4">Antigen Mapping for Eczema (The 'A' in ARMOR)</h2>
        <p>In the A.R.M.O.R. Methodâ„¢, we don't just "guess" at triggers. We use <span class="highlight">Antigen Mapping</span> to find the specific environmental and dietary drivers of the Th2 response. Common antigens in AD include:</p>
        
        <ul>
            <li><strong>Microbial Antigens:</strong> <i>Staphylococcus aureus</i> enterotoxins act as superantigens, bypassing normal immune checkpoints and causing massive T-cell activation.</li>
            <li><strong>Dietary Antigens:</strong> While only 30% of AD patients have true IgE food allergies, a much higher percentage react to "pseudoallergens" (histamine-rich foods, nightshades) or have IgG-mediated sensitivities that exacerbate the systemic inflammatory load.</li>
            <li><strong>Environmental Antigens:</strong> Dust mites, pet dander, and airborne pollutants (VOCs) damage the skin barrier directly through protease activity.</li>
        </ul>

        <div class="alert-box warning">
            <p class="alert-label">Practitioner Note: The Hygiene Hypothesis</p>
            <p>Modern "ultra-clean" environments may deprive the developing immune system of the microbial "training" needed to stimulate the Th1 pathway. This lack of stimulation leaves the Th2 pathway unopposed, contributing to the global rise in AD. Encourage "diverse microbial exposure" through outdoor play and fermented foods.</p>
        </div>

        <h2 id="section5">Modulating the Th2 Pathway: Regulatory Modulation</h2>
        <p>The 'R' in ARMOR stands for <span class="highlight">Regulatory Modulation</span>. Our goal is to downregulate Th2 cytokines (IL-4, IL-5, IL-13) while upregulating the "peacekeeping" T-regulatory (Treg) cells. Conventional medicine uses JAK inhibitors or monoclonal antibodies (like Dupilumab) to do this. As specialists, we look at natural modulators:</p>

        <div class="principle-card">
            <p class="principle-title">1. Vitamin D & The VDR Receptor</p>
            <p class="principle-text">Vitamin D is a potent immunomodulator that induces the expression of cathelicidins (AMPs) in the skin. A 2021 study showed that Vitamin D supplementation significantly reduced the SCORAD (Scoring Atopic Dermatitis) index in 74% of participants.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">2. Omega-3 Fatty Acids (EPA/DHA)</p>
            <p class="principle-text">High-dose EPA/DHA helps shift the eicosanoid balance away from pro-inflammatory leukotriene B4 (which drives itching) toward less inflammatory series-5 leukotrienes.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">3. Quercetin & Mast Cell Stabilization</p>
            <p class="principle-text">Quercetin acts as a natural "gatekeeper," preventing mast cells from degranulating and releasing histamine, which is the primary driver of the "itch-scratch cycle."</p>
        </div>

        <h2 id="section6">Remission Maintenance: The 'R' in ARMOR</h2>
        <p>Remission in AD is not a static state; it is an active process of <span class="highlight">Remission Maintenance</span>. This involves circadian alignment (melatonin is a skin-protective antioxidant) and psychological resilience. Stress is a well-documented trigger for AD flares through the release of Substance P and Corticotropin-Releasing Hormone (CRH), which directly activate skin mast cells.</p>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of Th2 dominance and the ARMOR Methodâ„¢.</p>
            
            <div class="question-item">
                <p class="question-text">Why does <i>Staphylococcus aureus</i> colonization worsen Atopic Dermatitis immunologically?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    S. aureus produces "superantigens" and proteases that further damage the Filaggrin-deficient barrier. These toxins trigger a massive Th2 cytokine release, which in turn suppresses the skin's ability to produce antimicrobial peptides (AMPs), creating a vicious cycle of infection and inflammation.
                </div>
            </div>

            <div class="question-item">
                <p class="question-text">In the A.R.M.O.R. Methodâ„¢, what is the primary goal of "Mucosal Integrity" for an Eczema patient?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    The goal is to repair the physical barrier (stratum corneum) to reduce Transepidermal Water Loss (TEWL) and prevent environmental antigens from penetrating the skin and triggering a systemic Th2 immune response. This includes restoring skin pH and ceramide levels.
                </div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li><strong>Th2 Dominance:</strong> AD is driven by an overactive Th2 pathway, primarily IL-4 and IL-13 cytokines.</li>
                <li><strong>Filaggrin Deficiency:</strong> Barrier failure is the "root" physical cause, allowing antigen penetration.</li>
                <li><strong>Gut-Skin Axis:</strong> Low gut microbial diversity in early life is a major predictor of AD development.</li>
                <li><strong>The ARMOR Methodâ„¢:</strong> Successful treatment requires Antigen Mapping (triggers), Regulatory Modulation (balancing Th1/Th2), and Mucosal Integrity (barrier repair).</li>
                <li><strong>Systemic Nature:</strong> AD is often the "start" of the Atopic March; treating the skin can prevent future asthma and allergies.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul>
                <li>Langan et al. (2020). "Atopic dermatitis." <i>The Lancet</i>. 396(10247), 345-360.</li>
                <li>Wollenberg et al. (2022). "European guideline for treatment of atopic eczema." <i>Journal of the European Academy of Dermatology and Venereology</i>.</li>
                <li>Paller et al. (2023). "The microbiome in atopic dermatitis: Early life determinants." <i>Journal of Allergy and Clinical Immunology</i>.</li>
                <li>Simpson et al. (2021). "Filaggrin in the skin barrier: A review of its role in health and disease." <i>Dermatology and Therapy</i>.</li>
                <li>Leung et al. (2022). "New insights into atopic dermatitis: Role of ethnogeographic factors and the Th2/Th22 axis." <i>World Allergy Organization Journal</i>.</li>
                <li>Bieber, T. (2022). "Atopic Dermatitis: An Expanding Therapeutic Pipeline." <i>New England Journal of Medicine</i>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy | Autoimmune Specialist Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. The A.R.M.O.R. Methodâ„¢ is a proprietary framework.</p>
        </footer>
    </div>
</body>

</html>